Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 25.42Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 25.42Mです。
赤字転落
同社の業績は赤字に転じ、最新の年間損失はUSD です。
適正水準
同社の最新のPEは-1.93で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は31.31M株で、前四半期比で4.58%減少しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は0.44です。